Compass Therapeutics, Inc.
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies. Its pipeline centers on bispecific and other proprietary antibodies designed to disrupt angiogenesis and tumor biology, with lead programs including tovecimig, CTX-471, CTX-8371, and CTX-10726.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLead and follow-on antibody candidates being advanced through clinical and IND-enabling development.
StitchMabsTM and related antibody discovery/engineering capabilities used to create bispecifics.
Milestones and other payments from partners for licensed product rights and development progress.
Customers
Compass Therapeutics does not yet sell approved products; its current economic counterparties are licensing partners, contract manufacturers, and clinical research vendors. If approved, its end customers would be physicians, hospitals, and third-party payors that influence adoption and reimbursement of oncology therapies.
Biopharma partners that pay milestones or royalties for rights to selected programs or geographies.
Hospitals, investigators, CROs, and vendors that support development of product candidates.
Physicians and cancer centers that would use approved products if the pipeline reaches market.
Insurers and reimbursement bodies that would influence uptake and net access after approval.
Strategy
The company is focused on advancing its antibody pipeline through clinical development while preserving optionality to partner selected rights by geography or program. Management also emphasizes capital discipline, noting that current cash is expected to fund operations into 2028, but additional financing or strategic transactions may still be needed to support development and eventual commercialization.
Clinical data and regulatory progress are the main value drivers for a pre-revenue biotech.
Regional or program-level deals can fund development and reduce capital burden.
The company expects to need substantial additional funding before product sales.
Geography
Compass Therapeutics is headquartered in Boston, Massachusetts and operates as a U.S.-based clinical-stage company with worldwide rights to most of its programs. The company relies on third-party manufacturers and research partners, and it has disclosed a China-linked milestone from Elpiscience tied to a Phase 1 trial, showing that development and partnering can extend beyond the U.S.
Risks
Compass Therapeutics is a pre-commercial biotech with no approved products, so its value depends on successful clinical development, regulatory clearance, and eventual market adoption. It also depends heavily on third parties for trials and manufacturing, and it faces typical oncology-biotech risks such as capital needs, intellectual property competition, and cybersecurity exposure.
- No products approved for commercial saleImpact: CriticalLikelihood: High
The company has a limited operating history and depends on pipeline success to create revenue.
Exposure: Entire business model
- Need for additional capitalImpact: HighLikelihood: High
R&D spending exceeds revenue and the company may need equity, debt, or partnerships to fund operations.
Exposure: Cash runway and development continuity
- Third-party trial and manufacturing dependenceImpact: HighLikelihood: Medium
The company relies on CROs and contract manufacturers for clinical studies and supply.
Exposure: Development timelines and regulatory readiness
- Cybersecurity and data privacyImpact: MediumLikelihood: Low
Research data, IP, and personal information are stored digitally and may be targeted or disrupted.
Exposure: Confidential data and operational continuity
- Intellectual property competitionImpact: Medium
Biotech competitors and larger pharma companies may develop similar oncology assets or challenge IP.
Exposure: Pipeline differentiation and partnering leverage
Accounting
Judgemental itemsManagement estimates progress on outsourced work, which affects current-period expense and liabilities.
Impact: Can shift expense timing between periods
Revenue depends on achievement of contractual milestones, creating lumpy and non-recurring recognition.
Impact: Can materially affect quarterly comparability
Equity awards are a meaningful operating cost for a development-stage biotech.
Impact: Affects operating loss and non-cash expense profile
Boston office and laboratory leases create fixed obligations and disclosure requirements.
Impact: Affects liquidity analysis and future cash outflows
Similar listed companies
Publicly listed companies with a comparable business focus.
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Immuneering Corp
IMRX · Pharmaceutical Preparations
Immuneering Corp is a clinical-stage biotechnology company focused on developing oncology therapies, with an emphasis on MAPK pathway cancers and biomarker-driven patient selection.
COMPASS Pathways plc
CMPS · Pharmaceutical Preparations
COMPASS Pathways plc is a clinical-stage biotechnology company focused on developing COMP360, a proprietary pharmaceutical-grade psilocybin treatment for serious mental health conditions.
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Compugen Ltd
CGEN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026